| scholarly article | Q13442814 |
| P50 | author | Kohei Kaku | Q47419459 |
| Yasuo Terauchi | Q88294909 | ||
| Masayuki Senda | Q89606169 | ||
| Yuji Kurihara | Q89606173 | ||
| Hisataka Fujiwara | Q91288050 | ||
| P2093 | author name string | Hideki Suganami | |
| Masahiro Tamura | |||
| Ryoji Gunji | |||
| P2860 | cites work | SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives | Q26746901 |
| A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond | Q26799389 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar | Q33612741 | ||
| Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes | Q34293786 | ||
| Tofogliflozin: first global approval | Q34420901 | ||
| Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus | Q36345951 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Liraglutide for weight management: a critical review of the evidence | Q37711170 | ||
| The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study | Q37737187 | ||
| Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans | Q37848043 | ||
| The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. | Q37940036 | ||
| Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. | Q38762377 | ||
| Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. | Q38912082 | ||
| Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised c | Q39368551 | ||
| Glycated albumin: a potential biomarker in diabetes. | Q39430493 | ||
| Safety and Effectiveness of Tofogliflozin in Elderly Japanese Patients with Type 2 Diabetes Mellitus: a Post-Marketing Study (J-STEP/EL Study). | Q40363925 | ||
| Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes | Q41184651 | ||
| Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience. | Q42082791 | ||
| Tofogliflozin: the road goes ever on. | Q42658161 | ||
| Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program | Q46110493 | ||
| A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. | Q47374718 | ||
| Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes. | Q50957907 | ||
| Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. | Q53094851 | ||
| Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. | Q53551539 | ||
| Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice | Q83629703 | ||
| SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM | Q85985011 | ||
| Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label | Q87261695 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 1518-1526 | |
| P577 | publication date | 2019-05-28 | |
| P1433 | published in | Journal of Diabetes Investigation | Q28207066 |
| P1476 | title | Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study | |
| P478 | volume | 10 |
Search more.